Overview
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
Status:
Completed
Completed
Trial end date:
2009-10-01
2009-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in children with non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for children who have non-Hodgkin's lymphoma.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Children's Oncology GroupCollaborators:
Children's Cancer and Leukaemia Group
National Cancer Institute (NCI)
Societe Francaise Oncologie PediatriqueTreatments:
Cortisol succinate
Cyclophosphamide
Cytarabine
Doxorubicin
Etoposide
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Liposomal doxorubicin
Methotrexate
Prednisolone
Prednisone
Vincristine
Criteria
DISEASE CHARACTERISTICS:- One of the following diagnoses:
- Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American
Lymphoma (REAL) categories II 9, 10, and 11, i.e.:
- Diffuse large cell
- Burkitt's
- High-grade B-cell, Burkitt's-like
- L3 leukemia with greater than 5% blasts in bone marrow
- No anaplastic large cell Ki1-positive lymphomas
- Immunophenotype and Murphy stage required prior to randomization
PATIENT CHARACTERISTICS:
Age:
- Over 6 months to under 21 years
- Maximum age 18 years in France and the United Kingdom
Other:
- No congenital immunodeficiency
- No prior organ transplantation
- No prior malignancy
- Not HIV positive
- Available for at least 36 months of follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Steroids initiated no more than 72 hours prior to entry allowed
- Bone marrow and cerebrospinal fluid examination required prior to steroids
Radiotherapy:
- Emergency radiotherapy initiated no more than 72 hours prior to entry allowed
Surgery:
- Not specified